Cullinan Therapeutics, Inc. - CGEM
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Mar 04, 2026 | SCHEDULE 13G | Kynam Capital Management, LP | 5.27% | 3,114,132 | View |
| Mar 04, 2026 | SCHEDULE 13G | Kynam Capital Management GP, LLC | 5.27% | 3,114,132 | View |
| Mar 04, 2026 | SCHEDULE 13G | Yue Tang | 5.27% | 3,114,132 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.6% | 3,302,376 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.6% | 3,302,376 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.8% | 2,271,662 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.8% | 2,271,662 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 224,641 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 224,641 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.4% | 5,574,038 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 5,918,481 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 5,918,481 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 5,918,481 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.58% | 3,298,504 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors LLC | 3.1% | 1,841,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors Holdings LP | 3.1% | 1,841,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel GP LLC | 3.1% | 1,841,079 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities LLC | 0.3% | 147,828 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities Group LP | 0.3% | 147,828 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities GP LLC | 0.3% | 147,828 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kenneth Griffin | 3.4% | 1,988,907 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | LYNX1 CAPITAL MANAGEMENT LP | 9.8% | 5,766,090 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | WESTON NICHOLS | 9.8% | 5,766,090 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Deerfield Mgmt, L.P. | 4.95% | 2,927,013 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Deerfield Management Company, L.P. | 4.95% | 2,927,013 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Deerfield Partners, L.P. | 4.95% | 2,927,013 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | James E. Flynn | 4.95% | 2,927,013 | View |
| Oct 30, 2025 | SCHEDULE 13G/A | The Vanguard Group | 4.98% | 2,943,325 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.